Stryker Co. (NYSE:SYK) Shares Purchased by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund raised its position in Stryker Co. (NYSE:SYK) by 0.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 29,405 shares of the medical technology company’s stock after purchasing an additional 54 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Stryker were worth $10,587,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Dunhill Financial LLC grew its holdings in Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares during the last quarter. Centricity Wealth Management LLC acquired a new stake in Stryker in the fourth quarter valued at $30,000. BankPlus Trust Department acquired a new stake in Stryker in the fourth quarter valued at $33,000. Darwin Wealth Management LLC acquired a new stake in Stryker in the third quarter valued at $36,000. Finally, Activest Wealth Management acquired a new stake in Stryker in the fourth quarter valued at $36,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

Stryker stock opened at $391.54 on Thursday. The stock’s 50-day moving average is $379.42 and its 200-day moving average is $370.37. The company has a market cap of $149.40 billion, a price-to-earnings ratio of 50.46, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the business posted $3.46 EPS. Equities analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. Stryker’s dividend payout ratio (DPR) is currently 43.30%.

Insider Activity

In other news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

SYK has been the topic of several recent research reports. Needham & Company LLC restated a “buy” rating and issued a $442.00 price objective on shares of Stryker in a research report on Wednesday, January 29th. The Goldman Sachs Group upped their price objective on Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a research report on Thursday, January 30th. BTIG Research upped their price objective on Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Citigroup restated a “buy” rating and issued a $450.00 price objective on shares of Stryker in a research report on Wednesday. Finally, Robert W. Baird upped their price objective on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $422.15.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.